Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA: Unapproved drugsBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 4/5. 16,609 PubMed citations indexed.
Endogenous redox coenzyme central to mitochondrial OXPHOS and critical substrate for sirtuins (SIRT1–7) and PARP enzymes regulating DNA repair and gene expression.
What the literature studies
Cellular Energy & Longevity
Evidence tier
Human RCT
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
Compounded IV NAD+ using food-grade ingredients linked to adverse events
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.